EUVIMEDEUVIMED entdecken
Open Access

Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer

Sida Huang, Sarah J Westvold, Pamela R Soulos, Jane Fan, Eric P Winer, Haiying Zhan, Maryam B Lustberg, John Lewin, Timothy J Robinson, Michaela A Dinan

JAMA Network Open · 15.04.2025 · 8 (4) · e255322

DOI: 10.1001/jamanetworkopen.2025.5322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 15.04.2025. Verfasst von Sida Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Public Health, New Haven, Connecticut. Hauptthemen laut MEDLINE: Breast Neoplasms, Mammography, Early Detection of Cancer, Mass Screening. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Screening mammography promotes early detection of breast cancer and is associated with reduced breast cancer mortality. Screening history prior to diagnosis may impact stage at diagnosis and breast cancer mortality but has not been comprehensively examined within a diverse US cohort.

Objective

To determine whether having a prior screening is associated with earlier stage at breast cancer diagnosis and lower breast cancer–specific mortality. Design, Setting, and Participants This cohort study used linked Surveillance, Epidemiology, and End Results–Medicare data of women aged at least 70 years, diagnosed with estrogen receptor–positive or human epidermal growth factor receptor 2–negative breast cancer from 2010 to 2017, and enrolled in fee-for-service Medicare Parts A and B from 5 years prior to through 1 year after diagnosis. Data were analyzed from March 1 to September 18, 2024. Exposure Presence of 1 or more screening mammograms during the 5 years prior to the mammogram at breast cancer diagnosis. Main Outcomes and Measures Outcomes of interest were stage of breast cancer at diagnosis, dichotomized into very early (T1N0) vs later stage (T2+ or N1+) and breast cancer–specific mortality.

Results

Among 13 028 included women, most had at least 1 prior screening (10 094 women [77.5%]) and were aged between 70 and 79 years (9034 women [69.4%]) and not dual-eligible for Medicare and Medicaid (11 475 women [88.1%]). Additionally, 3812 women (29.3%) were diagnosed with later-stage disease (T2+ or N1+) at the time of diagnosis. In multivariable analyses, prior screening was associated with 54% lower odds of later-stage breast cancer diagnosis (adjusted odds ratio, 0.46; 95% CI, 0.42-0.50) and 36% lower hazard of breast cancer–specific death (adjusted hazard ratio, 0.63; 95% CI, 0.52-0.76) compared with no prior screenin. In the adjusted Cox proportional hazards model, having 3 or 4 prior screenings was associated with 37% reduced hazard of breast cancer–specific mortality compared with having 1 prior screening (adjusted hazard ratio, 0.63; 95% CI, 0.44-0.89). Conclusions and Relevance In this cohort study of older women with screen-detected estrogen receptor–positive or human epidermal growth factor receptor 2–negative breast cancer, prior screening mammography was associated with earlier stage at breast cancer diagnosis and lower breast cancer mortality. These findings support the potential for routine screening to improve breast cancer outcomes. As with all observational studies, this study is limited by the potential effects of other differences between the screening and nonscreening groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMammographyEarly Detection of CancerMass ScreeningHumansFemaleAgedUnited StatesSEER ProgramNeoplasm StagingMedicareAged, 80 and overCohort Studies

Autor:innen und Institutionen

  • Yale School of Public Health, New Haven, Connecticut.
  • Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, Connecticut.
  • Yale Cancer Center, New Haven, Connecticut.
  • Department of Medical Oncology, Yale School of Medicine, New Haven, Connecticut.
  • Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
  • Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut.

Zitieren

APA

Huang, S., Westvold, S. J., Soulos, P. R., Fan, J., Winer, E. P., Zhan, H., Lustberg, M. B., Lewin, J., Robinson, T. J., & Dinan, M. A. (2025). Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer. JAMA Network Open, 8(4), e255322. https://doi.org/10.1001/jamanetworkopen.2025.5322

Vancouver

Huang S, Westvold SJ, Soulos PR, Fan J, Winer EP, Zhan H, et al. Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer. JAMA Network Open. 2025;8(4):e255322. doi:10.1001/jamanetworkopen.2025.5322

BibTeX
@article{Huang2025,
  author = {Huang, Sida and Westvold, Sarah J and Soulos, Pamela R and Fan, Jane and Winer, Eric P and Zhan, Haiying and Lustberg, Maryam B and Lewin, John and Robinson, Timothy J and Dinan, Michaela A},
  title = {Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {4},
  pages = {e255322},
  doi = {10.1001/jamanetworkopen.2025.5322}
}
Kostenlos starten →